Thrombopoietin: Biology and Potential Clinical Applications

ONCOLOGY

Volumn 12, Issue 11, 1998, Pages 1597-1608

  Prow, Debra ^a   Vadhan Raj, Saroj ^b  

^a Department of Genitourinary ^*

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOPOIETIN;

BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER; CANCER CHEMOTHERAPY; DRUG USE; HUMAN; REVIEW; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANIMALS; BLOOD PLATELETS; CLINICAL TRIALS; HEMATOPOIESIS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 0031797309     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Elias A, Ryan L, Aisner J, et al: Mesna. Doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma Semin Oncol 17(2 suppl 4):41-49, 1990.
2. Schutte J, Mouridsen H, Stewart W, et al: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 31(suppl 2):204-209, 1993.
3. Hill M, Macfarlane V, Moore J, et al: Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. Semin Oncol 24(1; suppl 2):34-37, 1997.
4. Veldhuis G, Williams P, Beijnew J, et al: Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony stimulating factor in ovarian cancer: A feasibility study. Br J Cancer 75(5):703-709, 1997.
5. Williams S, Birch R, Einhorn L, et al: Treatment of disseminated germ-cell tumor with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987.
6. Loehrer P, Lauer R, Roth B, et al: Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540-546, 1988.
7. Krigel R, Palackdharry C, Padavic K, et al: Ifosfamide, carboplatin and etoposide plus granulocyte colony-stimulating factor: A phase I study with apparent activity in non-small-cell lung cancer. J Clin Oncol 12:1251-1258, 1994.
8. Bonadonna G, Valagussar P, Santos A: Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med 104:739-746, 1986.
9. Goss P, Shepherd F, Scott G, et al: Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: Preliminary report of a phase II study. Ann Oncol 2(suppl 1):43-46, 1991.
10. Dana B, Dahlberg S, Miller T, et al: M-BACOD treatment for intermediate and high-grade malignant lymphoma: A Southwest Oncology Group phase II trial. J Clin Oncol 8:1155-1162, 1990.
11. Pruesser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer J Clin Oncol 7(9):1310-1317, 1989.
12. Bernstein SH, Nademanee A, Vose J, et al: A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem-cell transplantation: Cytokine growth factors in hematology and oncology. Blood 91(9):3509-3517, 1998.
13. Wallace EL, Churchill WH, Suregenor DM, et al: Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 35:802-812, 1995.
14. Heyman MR, Schiffer CA: Platelet transfusion therapy for the cancer patient. Semin Oncol 17:198-209, 1990.
15. Malone D, Sullivan S, Black D, et al: The cost of treating chemotherapy-induced thrombocytopenia (abstract). Proc Am Soc Clin Oncol 14:305, 1995.
16. Kuter DJ: The physiology of platelet production. Stem Cells 14(suppl 1):88-101, 1996.
17. Gewirtz A: Megakaryocytopoiesis: The state of the art. Thromb Haemost 74(1):204-209, 1995.
18. Hoffman R, Murray L, Young J, et al: Hierarchical structure of human megakaryocyte progenitor cells. Stem Cells 14(suppl 1):75-81, 1996.
19. Kelemen E, Cserhati I, Tanos B: Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 20:350-355, 1958.
20. Vignon I, Mornon J, Cocault L, et al: Molecular cloning and characterizations of Mpl, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor superfamily. Proc Natl Acad Sci USA 89:5640, 1992.
21. Wendling F, Varlet P, Charon M, et al: A retrovirus complex inducing an acute myeloproliferative leukemia disorder in mice. Virology 149:242, 1986.
22. Souyri M, Vigon I, Penciolelli JF, et al: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63:1137-1147, 1990.
23. Methia N, Louache F, Vainchenker W, et al: Oligodeoxynucleotides antisense to the proto-oncogene c-Mpl specifically inhibits in vitro megakaryocytopoiesis. Blood 82:1395-1401, 1993.
24. Bartley TD, Bogenberg J, Hunt P, et al: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77:1117-1124, 1994.
25. de Savage FJ, Hass PB, Spencer SD, et al: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533-538, 1994.
26. Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 91:11104-11108, 1994.
27. Lok S, Kaushansky K, Holly RD, et al: Cloning and expression of murine thrombopoietin CDNA and stimulation of platelet production in vivo Nature 369:565-568, 1994.
28. Sohma Y, Akahori H, Seki N, et al: Molecular cloning and chromosomal localization of the human thrombopoietin gene. Federation of European Biochemical Societies Lett 353:57-61, 1994.
29. Wendung F, Maraskovsky E, Debili N, et al: c-Mpl ligand as a humoral regulator of megakaryopoiesis. Nature 369:571-574, 1994.
30. Chang M, McNinch J, Basu R, et al: Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene. J Biol Chem 270(2):511-514, 1995.
31. Foster D, Lok S: Biological roles for the second domain of thrombopoietin. Stem Cells 14(suppl 1):102-107, 1996.
32. Debili N, Wendung F, Cosman, et al: The Mpl receptor is expressed in the megakaryocyte lineage from later progenitors to platelets. Blood 85:391, 1995.
33. Le Conniat M, Souyri M, Vigon I, et al: The human homolog of the myeloproliferative leukemia virus maps to chromosome band 1p34. Hum Genet 83:194-196, 1989.
34. Gurney A, de Sauvage F: Dissection of c-Mpl and thrombopoietin function: Studies of knockout mice and receptor signal transduction. Stem Cells 14(suppl 1):116-123, 1996.
35. Kaushansky K, Lok S, Holly RD, et al: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568-571, 1994.
36. Broudy VC, Lin NL, Kaushansky K: Thrombopoietin (c-Mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719, 1995.
37. Kaushansky K, Broudy VC, Lin N, et al: Thrombopoietin, the Mpl-ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 92:3234-3238, 1995.
38. Ziegler FC, de Sauvage F, Widmer HR, et al: In vitro megakaryocytopoietic and thrombopoietic activity of c-Mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 84:4045, 1994.
39. Zucker-Franklin D: Megakaryocyte and platelet structure in thrombocytopoiesis: The effect of cytokines. Stem Cells 14(suppl 1):1-17, 1996.
40. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 86(2):419-431, 1995.
41. Kobayashi M, Layer HJ, Kato T, et al: Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors. Blood 86:2494-2499, 1995.
42. Sitnicka B, Lin N, Priestley GV, et al: The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 87:87:4998-5005, 1996.
43. +Lin primitive progenitor cells. Blood 88:1619-1631, 1996.
44. Ramsfjell V, Borge OJ, Vieby OP, et al: Thrombopoietin, but not erythropoietin, directly stimulates multi-lineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: Distant interactions with the ligands for c-kit and FLT3. Blood 88(12):4481-4492, 1996.
45. Kuter DJ, Rosenberg RD: The appearance of a megakaryocyte growth promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 84:1464-1472, 1995.
46. Cohen-Solal K, Villeval J-L, Titeux M: Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 88:2578-2584, 1996.
47. Nichol JL, Hokom MM, Homkohl A, et al: Megakaryocyte growth and development factor: Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 95:2973-2979, 1995.
48. Meng YG, Martin TG, Peterson ML: Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br J Haematol 95(3):535-544, 1996.
49. Emmons R, Reid DM, Cohen RL: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87:4068-4071, 1996.
50. Gurney AL, Caver-Moore K, de Sauvage FJ, et al: Thrombocytopenia in c-Mpl-deficient mice Science 265:1445-1447, 1994.
51. de Sauvage F: Physiologic regulation of early and late stages of megakaryocytosis by thrombopoietin. J Exp Med 183:651-656, 1996.
52. Alexander WS, Roberts AW, Nicola NA: Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl. Blood 87:2162-2170, 1996.
53. Carver-Moore K, Broxmeyer HE, Luoh SM: Low levels of erythroid and myeloid progenitors in thrombopoietin and c-Mpl-deficient mice. Blood 88:803-808, 1996.
54. Gurney A, deSauvage F: Dissection of c-Mpl and thrombopoietin function: Studies of knockout mice and receptor signal transduction. Stem Cells 14(suppl 1):116-123, 1996.
55. Fielder P, Gurney A, Stefanich E, et al: Regulation of thrombopoietin levels by c-Mpl-mediated binding to platelets. Blood 87:2154-2161, 1996.
56. Tahara T, Usuki K, Sato H, et al: A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and in patients with haematopoietic disorders. Br J Haematol 93:783-788, 1996.
57. Kaushansky K, Lin N, Grossman A, et al: Thrombopoietin expands erythroid, granulocyte-macrophage and megakaryocytic progenitor cells in normal myelosuppressed mice. Exp Hematol 24(2):265-269, 1996.
58. Ulich TR, del Castillo J, Yin S, et al: Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 86:971-976, 1995.
59. Hokom MM, Lacey D, Kinstler O, et al: Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 86:4486-4492, 1995.
60. Thomas GR, Thibodeaux H, Errett CJ, et al: In vivo biological effects of various forms of thrombopoietin in a murine model of transient pancytopenia. Stem Cells 1:245-266, 1996.
61. Farase A, Hunt P, Boone T, et al: Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 86:54-59, 1995.
62. Nichol J: Preclinical biology of megakaryocyte growth and development factor: A summary. Stem Cells 14(suppl 1):48-52, 1996.
63. Basser R, Rasko J, Clarke K, et al: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-HuMGDF) in patients with advanced cancer. Lancet 348:1279-1281, 1996.
64. Basser R, Rasko J, Clarke K, et al: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118-3128, 1997.
65. Fanucchi M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404-409, 1997.
66. Crawford J, Glaspy J, Belani C, et al: A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim support in non-small-cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy (abstract). Proc Am Soc Clin Oncol 17:73a, 1998.
67. Vadhan-Raj S, Patel S, Broxmeyer HE, et al: Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high-dose chemotherapy with Adriamycin and ifosfamide. Blood 88:448a, 1996.
68. Vadhan-Raj S, Murray L, Bueso-Rumos C, et al: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126:673-681, 1997.
69. Vadhan-Raj S, Verschraegen C, McGarry L, et al: Recombinant human thrombopoitin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecologic malignancy (abstract). Blood 90:580a, 1997.
70. Connors J, Curie LM, Allan H, et al: Recovery of in vitro functional activity of platelet concentrates stored at 4°C and treated with second-messenger effectors. Transfusion 36:691-698, 1996.
71. Currie LM, Vadhan-Raj S, and Connor J: Cryopreservation of platelets from recombinant human thrombopoietin (rhTPO)-treated donors using thrombosol and 2% DMSO. J Am Soc Hematol 88(suppl 1):1316, 1996.
72. Kuter D: Thrombopoietin: Biology, clinical applications, role in the donor setting. J Clin Apheresis 11(3):149-159, 1996.
73. Siemensma NP, Bathal PS, Penington DG: The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med 86:817-833, 1975.
74. Ezumi Y, Takayama H, Okuma M, Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2 and STAT3, and enhances agonist-induced aggregation in platelets in vitro. Federation of European Biochemical Societies Lett 3 74:48-52, 1995.
75. Toombs CF, Young CH, Glaspy JA: Megakaryocyte growth and development factor (MGDF) moderately enhances in vitro platelet aggregation. Thromb Res 80:23-33, 1995.
76. Yan X-Q, Lacey D, Fletcher, et al: Chronic exposure to retroviral vector encoded MGDF (mpl-Ligand) induces lineage-specific growth and differentiation of megakarocytes in mice. Blood 88:4025-4033, 1995.
77. Columbyova L, Loda M, Scadden DT: Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 55:3509-3512, 1995.
78. Vigon I, Dreyfus F, Melle J, et al: Expression of the c-Mpl protooncogene in human hematologic malignancies. Blood 82:877-883, 1993.